Valuation: Fortress Biotech, Inc.

Market Cap	6.84Cr 6.07Cr 5.68Cr 5.15Cr 9.72Cr 659.07Cr 9.79Cr 68Cr 27Cr 336.22Cr 26Cr 25Cr 1.08TCr	P/E 2026 *	0.8x	P/E 2027 *	-2.05x
Enterprise Value	6.84Cr 6.07Cr 5.68Cr 5.15Cr 9.72Cr 659.07Cr 9.79Cr 68Cr 27Cr 336.22Cr 26Cr 25Cr 1.08TCr	EV / Sales 2026 *	0.87x	EV / Sales 2027 *	0.6x
Free-Float	77.3%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news: Fortress Biotech, Inc.

14/08	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
13/08	Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026
15/05	Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/04	Journey Medical Corporation secures contract with third major GPO for Emrosi	RE
01/04	Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
31/03	Fortress Biotech Unit Closes $205 Million PRV Sale	MT
23/02	Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million	MT
13/01	Fortress Biotech shares hit near two-week low, last down 6.6%	RE
13/01	Fortress Biotech seen surging after FDA approval
13/01	Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo	CI
13/01	Fortress Biotech, Cyprium Say FDA Approved Zycubo for Pediatric Patients of Menkes Disease; Shares Rise Pre-Bell	MT
13/01	US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease	RE
13/01	Fortress Biotech and Cyprium Therapeutics announce U.S. FDA approval of Zycubo® (copper histidinate), the first and only approved treatment for Menkes disease in the United States	RE

More news

Last Transcript: Fortress Biotech, Inc.

Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026

13/08

More transcripts

Analysts' recommendations: Fortress Biotech, Inc.

01/25/01	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101	CI
01/25/01	Fortress Biotech Shares Drop After FDA Letter for CUTX-101 Manufacturing Facility	DJ
01/25/01	Fortress Biotech and Cyprium Therapeutics announce an update on the NDA for CUTX-101	RE
19/24/19	Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	MT
29/23/29	Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	MT

More recommendations

Press Releases: Fortress Biotech, Inc.

09/09	Journey Medical Corporation to Participate in September 2026 Investor Conferences	AQ
08/09	Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
14/08	Fortress Biotech: Q2 Earnings Snapshot	AQ
14/08	Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ
13/08	Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ

More press releases

News in other languages: Fortress Biotech, Inc.

13/01	Fortress Biotech attendu en forte hausse après une approbation de la FDA
29/21/29	MÄRKTE USA/Nur maue Erholung - Belastungsfaktoren bleiben
29/21/29	MÄRKTE USA/Moderate Erholung von Vortagesabsturz
30/20/30	Israël limite les manifestations dans le cadre de mesures sanitaires
30/20/30	France : l'inflation a ralenti à 0,1% sur un an en septembre

More news

Managers and Directors: Fortress Biotech, Inc.

Manager	Title	Age	Since
Lindsay Rosenwald CEO	Chief Executive Officer	71	20/12/2013
Xiao Qin Lu DFI	Director of Finance/CFO	51	22/02/2012
David Jin DFI	Director of Finance/CFO	36	16/08/2022

Director	Title	Age	Since
Jimmie Harvey BRD	Director/Board Member	74	01/12/2008
Lindsay Rosenwald CHM	Chairman	71	20/12/2013
J. Jay Lobell BRD	Director/Board Member	63	01/06/2006

More insiders

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13RÎ±2 CAR T Cell Program for Glioblastoma), and others.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
06/26/06	$2.050	-1.91%	2,23,985
05/26/05	$2.090	+2.96%	5,53,819
02/26/02	$2.030	-1.93%	3,27,172
01/26/01	$2.070	-3.27%	2,86,248
30/26/30	$2.140	-2.73%	2,21,331

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.050USD

Average target price

5.000USD

Spread / Average Target

+143.90%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Fortress Biotech, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Fortress Biotech, Inc.

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq 01:30:00 07/10/2026 am IST			5-day change	1st Jan Change
2.050 ^USD	-1.91%		-6.82%	-43.99%

Markets		Quality
Nasdaq	FBIO	Delayed
CBOE	FBIO	Real-time

1 day	-1.91%
1 week	-6.82%
Current month	-4.21%
1 month	-24.63%
3 months	-30.51%
6 months	-18.33%
Current year	-43.99%

1 week	2	2.17
1 month	2	2.75
Current year	2	4.53
1 year	2	4.53
3 years	1.24	4.95
5 years	1.24	55.35
10 years	1.24	91.5

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/10/26	David Jin	Free	Chief Financial Officer	1,190	0.0036%
01/04/26	David Jin	Free	Chief Financial Officer	2,967	0.0096%
18/03/26	Lindsay Rosenwald	Free	Chief Executive Officer	4,75,424	1.5318%

Fortress Biotech, Inc. Share Price

Stocks

FBIO

US34960Q3074

Pharmaceuticals

Valuation: Fortress Biotech, Inc.

Chart: Fortress Biotech, Inc.

Latest news: Fortress Biotech, Inc.

Last Transcript: Fortress Biotech, Inc.

Analysts' recommendations: Fortress Biotech, Inc.

Press Releases: Fortress Biotech, Inc.

News in other languages: Fortress Biotech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Fortress Biotech, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FORTRESS BIOTECH, INC.	-1.91%	-6.82%	-34.08%	-58.21%	6.84Cr
ELI LILLY AND COMPANY	+1.26%	-2.29%	+36.97%	+104.79%	1,03200Cr
JOHNSON & JOHNSON	+0.73%	-4.78%	+35.41%	+61.62%	61TCr
ABBVIE INC.	+0.35%	+1.29%	+15.86%	+79.90%	47TCr
MERCK & CO., INC.	+1.72%	-4.92%	+59.84%	+36.64%	35TCr
ROCHE HOLDING AG	+0.29%	+0.14%	+21.29%	+40.99%	34TCr
NOVARTIS AG	+0.51%	-3.09%	+10.76%	+32.59%	27TCr
ASTRAZENECA PLC	-0.33%	-3.78%	-6.03%	+9.29%	25TCr
AMGEN INC.	-0.09%	-4.97%	+36.88%	+50.52%	22TCr
GILEAD SCIENCES, INC.	-0.28%	-4.66%	+26.99%	+92.98%	18TCr
Average	-0.04%	-3.73%	+20.39%	+45.11%	37.15TCr
Weighted average by Cap.	-0.07%	-3.18%	+29.54%	+66.99%

	2026 *	2027 *
Net sales	7.88Cr 6.99Cr 6.55Cr 5.93Cr 11Cr 759.56Cr 11Cr 79Cr 31Cr 387.48Cr 30Cr 29Cr 1.25TCr	11Cr 10Cr 9.41Cr 8.53Cr 16Cr 1.09TCr 16Cr 112.99Cr 44Cr 556.93Cr 43Cr 42Cr 1.79TCr
Net income	8.82Cr 7.83Cr 7.33Cr 6.64Cr 13Cr 850.69Cr 13Cr 88Cr 34Cr 433.97Cr 33Cr 32Cr 1.4TCr	-3.78Cr -3.36Cr -3.14Cr -2.85Cr -5.38Cr -364.52Cr -5.42Cr -38Cr -15Cr -185.96Cr -14Cr -14Cr -597.81Cr
Net Debt	-	-